-->

Tag: Progression-Free Survival

Home / Progression-Free Survival

Categories

Ensartinib is approved by the USFDA for ALK-positive locally advanced or metastatic non-small cell lung cancer

 On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or ...
progression-free-survival

Isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone is approved by the USFDA for newly diagnosed multiple myeloma

 On September 20, 2024, the Food and Drug Administration sanctioned isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) in conjunction with bortezomib, lenalidomide, and dexamethasone for people with...
progression-free-survival

Scan the code